trial

Antipsychotic Polypharmacy in Schizophrenia

NCTId NCT00493233
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 100 (estimated)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-11
Primary completion
2008-12
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
—

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
Canadian Psychiatric Research FoundationCollaborator

Investigators

1
David C. Mamo, MD, MScPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
100
Phase
NA
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
Canadian Psychiatric Research Foundation
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David C. Mamo, MD, MSc
person